The FDA has cleared Oncoc4 Inc.’s IND application for ONC-841, a potential first-in-class Siglec-10-blocking antibody for the treatment of solid tumors.
Immuneoncia Therapeutics Inc., a joint venture between South Korea’s Yuhan Corp. and San Diego-based Sorrento Therapeutics Inc., is looking to list on the Korea Exchange, having recently passed local technology evaluation.
Researchers from Adcentrx Therapeutics Inc. recently reported preclinical data for the Nectin-4-targeting antibody-drug conjugate (ADC) ADRX-0706, currently in phase I development for the treatment of solid tumors (NCT06036121).
Barinthus Biotherapeutics plc’s immunotherapeutic against persistent, high-risk human papillomavirus (HPV) infections, VTP-200, was generally well-tolerated in a phase Ib/II study, but did not demonstrate significant signs of efficacy, pooled top-line data show.
Pathios Therapeutics Ltd. has raised $25 million in the first close of a series B financing. Proceeds will support continued development of Pathios’ unique approach to cancer immunotherapy focused on GPR65 inhibition.
Researchers from Zhuhai Grit Biotechnology Co. Ltd. recently presented preclinical characterization of a new genetically modified tumor-infiltrating lymphocyte (TIL) product, GT-216, being developed for the treatment of solid tumors.
CD276-based immunotherapy strategies have demonstrated potent antitumor activity and feasibility for clinical application in solid tumors. In urothelial bladder cancer, CD276 is also aberrantly expressed. However, the exact role of CD276 in bladder cancer tumorigenesis and its potential clinical significance remain unexplored.
Immuneoncia Therapeutics Inc., a joint venture between South Korea’s Yuhan Corp. and San Diego-based Sorrento Therapeutics Inc., is looking to list on the Korea Exchange, having recently passed local technology evaluation.
The leukocyte immunoglobulin-like receptor B2 (LILRB2), also known as ILT4, is an immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing receptor that is widely expressed on immunosuppressive myeloid cells in the tumor microenvironment.
RSS
.webp?height=488&t=1670008838&width=650 "Acute myeloid leukemia")
